Literature DB >> 5442346

Mode of action of the cytostatic agent "ICRF 159".

H B Sharpe, E O Field, K Hellmann.   

Abstract

Mesh：

Substances：

Year:  1970        PMID： 5442346     DOI： 10.1038/226524a0

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  21 in total

1.  Combined razoxane and radiotherapy for melanoma brain metastases. a retrospective analysis.

Authors:  Walter Rhomberg; Helmut Eiter; Franz Boehler; Christoph Saely; Robert Strohal
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

2.  Effect of ICRF 159 on immune responses.

Authors:  K Hellmann
Journal:  Proc R Soc Med       Date:  1972-03

3.  Inhibition of metastatic spread by I.C.R.F. 159: selective deletion of a malignant characteristic.

Authors:  A J Salsbury; K Burrage; K Hellmann
Journal:  Br Med J       Date:  1970-11-07

4.  Razoxane in treatment of acute myeloid leukaemia.

Authors: 
Journal:  Br Med J       Date:  1978-10-21

5.  Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors.

Authors:  C L Vogel; E Gorowski; E Davila; M Eisenberger; J Kosinski; R P Agarwal; N Savaraj
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

6.  Responses of liver metastases to radiotherapy and razoxane.

Authors:  K Hellmann; M Goold; N Higgins; R H Phillips
Journal:  J R Soc Med       Date:  1992-03       Impact factor: 5.344

7.  Antitumor activity of MST-16, a novel derivative of bis(2,6-dioxopiperazine), in murine tumor models.

Authors:  T Narita; S Yaguchi; T Komatsu; M Takase; A Hoshino; M Inaba; S Tsukagoshi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  The cytokinetic and cytotoxic effects of ICRF-159 and ICRF-187 in vitro and ICRF-187 in human bone marrow in vivo.

Authors:  R H Wheeler; D J Clauw; R B Natale; R W Ruddon
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

9.  Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp.

Authors:  J Roca; R Ishida; J M Berger; T Andoh; J C Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-01       Impact factor: 11.205

10.  [The effect of bleomycin, ICRF 159 and of simultaneous X-ray application on CHO-fibroblasts].

Authors:  D Töllner; G Hagemann
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1977
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.